Allergan Faces Improper Marketing Penalties
 

      Allergan has agreed to pay $600m for the off-label marketing of its botox drug.

     The company has been the focus of allegations resulting from the promotion of its botox medication for uses other than what the US Food and Drug Administration (FDA) approved, in which the firm marketed the drug in the US to treat headaches, overactive bladders and spasticity.

     As part of the agreement, the pharmaceutical company will pay a number of US states and the federal government a sum of $225m, with $33m for Medicaid.

     The US attorney for the northern gistrict of Georgia also alleged a misdemeanour violation of the Food, Drug and Cosmetic Act, causing Allergan to accept a plea agreement and an additional $350m in criminal fines and $25m in forfeiture.